Itraconex-200

Therapeutic Class:
Dosage Forms:
  • Itraconazole Capsule 200 mg

How it works ?

Itraconazole Capsule 200 mg use Vulvovaginal candidiasis, Oropharyngeal candidosis, Pityriasis versicolor,Systemic candidiasis, Histoplasmosis, Dermatophytoses caused by organisms susceptible to itraconazole (Trichophyton spp., Microsporum spp.,Epidermophyton floccosum) e.g. tinea pedis, tinea cruris, tinea corporis, tinea manuum, Onychomycoses caused by dermatophytes and/or yeasts, Cryptococcal infections (including cryptococcal meningitis). In immunosuppressed patients suffering fromcryptococcosis and in patients with cryptococcosis of the CNS Itraconazole is indicated only if the usually recommendedinitial therapy seems to be inappropriate or ineffective. Aspergillosis. Itraconazole can be used to treat patients suffering from invasive aspergillosis who were found to berefractory or intolerant to Amphotericin B. Maintenance therapy in AIDS patients to prevent relapse of underlying fungal infection who were found to be refractoryor intolerant to first-line systemic anti-fungal therapy is inappropriate or has proved ineffective.
Itraconazole Capsule 200 mg is for oral administration and must be taken immediately after a meal for maximal absorption. The capsulesmust be swallowed whole.
Abdominal Pain, Nausea, Uncommon:Vomiting, Diarrhoea, Constipation, Dyspepsia, Dysgeusia, Flatulence, Rash,.
There is no information regarding cross hypersensitivity between itraconazole and other azole antifungal agents. Cautionshould be used in prescribing Itraconazole Capsule 200 mg Capsules to patients with hypersensitivity to other azoles. Itraconazole has been shown to have a negative inotropic effect and has been associated withreports of congestive heart failure. Itraconazole should not be used in patients with congestive heart failure or with a history of congestive heart failure unlessthe benefit clearly outweighs the risk. Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should beexercised when the drug is administered in this patient population. It is recommended that patients with impaired hepaticfunction be carefully monitored when taking itraconazole. Clinical data on the use of itraconazole in paediatric and elderly patients is limited.The use of Itraconazole inpaediatric and elderly patients is not recommended unless it is determined that the potential benefit outweighs the potential risks. Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several ofthese reports included concurrent administration of quinidine which is contraindicated. The hearing loss usually resolves when treatment is stopped,but can persist in some patients. Due to the pharmacokinetic properties, itraconazole capsules are notrecommended for initiation of treatment in patients with immediately life-threatening systemic fungal infections. In systemic candidosis, if fluconazole-resistant strains of Candida species are suspected, it cannot be assumed thatthese are sensitive to itraconazole, hence their sensitivity should be tested before the start of Itraconex-200 therapy. If neuropathy occurs which may be attributable to itraconazole Capsules, the treatment should be discontinued. In patients with AIDS having received treatment for a systemic fungal infection such as sporotrichosis, blastomycosis,histoplasmosis or cryptococcosis (meningeal or non-meningeal) and who are considered at risk for relapse, the treatingphysician should evaluate the need for a maintenance treatment.
Store below 30°C, protect from light and moisture Keep the medicine out of reach of children.
10 x 10 Alu/PVC blister pack Itraconex-200 is available in an Alu/PVC blister of 10 capsules. Such 10 blisters in a unit carton with package insert.

F. A. Q

Frequently Asked Questions

Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.

We have below MOQ for:

  1. Tablet, Capsules & Softgel: 200000 Units
  2. Ampoules : 100000 Units
  3. Vials: 10000 Units
  4. Ointment and Cream: 15000 Units
  5. Suppository: 50000 Units
  6. Syrup and Liquid: 10000 Units
  7. Sachets : 50000 Units

We do ready the product within 45-60 days after product artwork confirmation from your side. So, including transit time you can get the product within 90 days maximum, either by Air or Sea route.

A product's “shelf life” generally means the length of time you can expect a product to look and act as expected and to stay safe for use. This length of time varies, depending on the type of product, how it is used, and how it is stored.

Our products come with a minimum of 24 months to a maximum of 36 months of shelf life.

For, Primary packaging we use aluminium foil with 20 to 50 micron size and PVC foil with 350 to 400 micron depending on product characteristics and stability.

For, Secondary packing we do use 300 to 400 GSM FFB Card board.

For, Tertiary packing we do us 7 ply 150 GSM corrugated boxes to prevent the damage during transits.

Yes, we do have available for all dossier documents according to GMP guidelines for the respective country. We do also provide COPP and Free sale certificates (FSC) on demand to customers for special import permit type of commercial orders.

interested? let’s talk.

Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.